Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study - Granit, V; Benatar, M; Kurtoglu, M (Lancet Neurol, 2023)